| Trial | Treatments | Patients | Method |
|---|
| GeparQuattro, 2010 | (n=-9) vs. (n=-9) | Patients with large operable or locally advanced tumors, with hormone receptor-negative tumors, or with receptor-positive tumors but also clinically node-positive disease | Sample size: -9/-9 Primary endpoint: FU duration: |
| Mavroudis, 2010 | docetaxel 75 mg/m(2) on day 1 plus capecitabine 950 mg/m(2) orally twice daily on days 1-14 (DC) in 21-day cycles (n=-9) vs. docetaxel 75 mg/m(2) plus epirubicin 75 mg/m(2) (DE) on day 1 (n=-9) | women with advanced breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| Joensuu, 2009 | three cycles of capecitabine and docetaxel followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (n=753) vs. three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (n=747) | women with axillary node-positive or high-risk node-negative breast cancer | open-label Sample size: 753/747 Primary endpoint: FU duration: |
| EORTC 10001 (Pajk), 2008 | capecitabine 1250 mg/m(2) orally bid days 1-14 (n=-9) vs. vinorelbine 30 mg/m(2) i.v. days 1 and 8, both given every 3 weeks (n=-9) | patients with anthracycline- and taxane-pretreated metastatic breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| Lee, 2008 | (n=-9) vs. (n=-9) | women with axillary node positive, stage II/III breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| Verma, 2005 | 21-day cycles of oral capecitabine 1250 mg/m2 twice daily, on Days 1-14, plus docetaxel 75 mg/m2 Day 1 (n=255) vs. docetaxel 100 mg/m2 on Day 1 (n=256) | patients with anthracycline-pretreated metastatic breast carcinoma | Sample size: 255/256 Primary endpoint: FU duration: |
| Miles, 2004 | (n=511) vs. (n=0) | patients with anthracycline-pretreated advanced/metastatic breast cancer | Sample size: 511/0 Primary endpoint: FU duration: |
| O'Shaughnessy, 2002 | 21-day cycles of oral capecitabine 1,250 mg/m(2) twice daily on days 1 to 14 plus docetaxel 75 mg/m(2) on day 1 (n=255) vs. docetaxel 100 mg/m(2) on day 1 (n=256) | patients with advanced breast cancer | Sample size: 255/256 Primary endpoint: FU duration: |
| Talbot, 2002 | intermittent oral capecitabine (1255 mg m(-2) twice daily, days 1-14, (22 patients)) (n=-9) vs. i.v. paclitaxel (175 mg m(-2), (n=-9) | patients with metastatic/advanced breast cancer pretreated with anthracyclines | Sample size: -9/-9 Primary endpoint: FU duration: |
| Oshaughnessy, 2001 | intermittent oral capecitabine 1,255 mg/m2 twice daily (two weeks' treatment followed by a one-week rest period) (n=-9) vs. intravenous CMF (cyclophosphamide. methotrexate, 5-fluorouracil [5-FU]) administered every three weeks (n=-9) | -line therapy for advanced/metastatic breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| Hori | capecitabine, + medroxyprogesterone acetate (MPA) + cyclophosphamide (n=-9) vs. 5-fluorouracil + adriamycin + CPA) plus MPA (n=-9) | metastatic breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
| Moiseenko, 2000 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Stockler, 2011 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
| Jäger, 2010 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
